 "pharma, pharma industry")
Dr Reddy’s Laboratories dipped 6% to Rs 2,470, extending its previous day’s 3% decline on BSE, after the company reported disappointing set of numbers for the quarter ended June 2017 (Q1FY18).
The consolidated net profit for the pharmaceutical company more- than-halved to Rs 59 crore in Q1FY18 against Rs 126 crore in the same quarter year ago. Revenue during the quarter under review grew 3% to Rs 3,316 crore from Rs 3,235 crore in year ago quarter.
Analysts on an average had expected profit of Rs 307 crore on revenues of Rs 3,399 crore for the quarter.
The consolidated net profit for the pharmaceutical company more- than-halved to Rs 59 crore in Q1FY18 against Rs 126 crore in the same quarter year ago. Revenue during the quarter under review grew 3% to Rs 3,316 crore from Rs 3,235 crore in year ago quarter.
Analysts on an average had expected profit of Rs 307 crore on revenues of Rs 3,399 crore for the quarter.
